What is Speclipse?
Founded in 2015 by Stanford alumnus Sung Hyun Pyun, Speclipse has established itself as a formidable force in the global medtech landscape. The company is distinguished by its sophisticated approach to non-invasive diagnostic imaging, earning accolades as a premier dermatology solution provider. By integrating deep clinical insights with cutting-edge engineering, Speclipse is effectively bridging the gap between laboratory-grade accuracy and point-of-care accessibility. Its expansion into blood analysis marks a significant evolution in its business model, positioning the firm to address a broader spectrum of chronic and acute health conditions. With a dual-headquarters structure in Sunnyvale and Seoul, the company maintains a global footprint that facilitates both technological innovation and rapid market penetration.
How much funding has Speclipse raised?
Speclipse has raised a total of $7.7M across 1 funding round:
Unspecified
$7.7M
Unspecified (2021): $7.7M with participation from MiCoBioMed, BNH Investment, MiCo, Shinhan Capital, and Signite Partners
Key Investors in Speclipse
MiCoBioMed
A specialized biotechnology firm focused on the development of advanced diagnostic equipment and molecular testing solutions.
BNH Investment
A venture capital firm with a strong track record in supporting high-growth healthcare and life sciences companies.
Shinhan Capital
A major financial institution providing strategic growth capital to innovative technology and healthcare enterprises.
What's next for Speclipse?
Looking ahead, Speclipse is poised to leverage its recent capital influx to accelerate the commercialization of its expanded diagnostic suite. The strategic roadmap focuses on validating its blood analysis technology through rigorous clinical trials and expanding its regulatory footprint in key international markets. As the company scales, it will likely prioritize partnerships with major healthcare providers to integrate its diagnostic tools into standard clinical practice. The ongoing support from its investor base suggests a long-term commitment to scaling the company's operational infrastructure, ensuring that Speclipse remains at the forefront of the diagnostic revolution. Future growth will be defined by the successful transition from a niche dermatology specialist to a diversified leader in the broader diagnostics industry.
See full Speclipse company page
